{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:23:52Z","timestamp":1766157832879},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T00:00:00Z","timestamp":1428192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s12185-015-1788-y","type":"journal-article","created":{"date-parts":[[2015,4,4]],"date-time":"2015-04-04T03:56:46Z","timestamp":1428119806000},"page":"379-382","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia"],"prefix":"10.1007","volume":"102","author":[{"given":"Toshihiko","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,5]]},"reference":[{"key":"1788_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","volume":"11","author":"JP Hwang","year":"2014","unstructured":"Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11:209\u201319.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1788_CR2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/annonc\/mdp230","volume":"20","author":"N Fukushima","year":"2009","unstructured":"Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013\u20137.","journal-title":"Ann Oncol"},{"key":"1788_CR3","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/sj.leu.2402567","volume":"16","author":"C Skrabs","year":"2002","unstructured":"Skrabs C, M\u00fcller C, Agis H, Mannhalter C, J\u00e4ger U. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia. 2002;16:1884\u20136.","journal-title":"Leukemia"},{"key":"1788_CR4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605\u201311.","journal-title":"J Clin Oncol"},{"key":"1788_CR5","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/jmv.22199","volume":"83","author":"N Coppola","year":"2011","unstructured":"Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909\u201316.","journal-title":"J Med Virol"},{"key":"1788_CR6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","volume":"2","author":"B Rehermann","year":"1996","unstructured":"Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104\u20138.","journal-title":"Nat Med"},{"key":"1788_CR7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1872-034X.2012.00998.x","volume":"42","author":"M Oketani","year":"2012","unstructured":"Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627\u201336.","journal-title":"Hepatol Res"},{"key":"1788_CR8","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1086\/590968","volume":"47","author":"T Umemura","year":"2008","unstructured":"Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52\u20136.","journal-title":"Clin Infect Dis"},{"key":"1788_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-013-1470-1","volume":"99","author":"S Fujisawa","year":"2014","unstructured":"Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014;99:141\u201353.","journal-title":"Int J Hematol"},{"key":"1788_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","volume":"19","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol. 2014;19:3\u20139.","journal-title":"Int J Clin Oncol"},{"key":"1788_CR11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s12185-014-1565-3","volume":"99","author":"M Aoe","year":"2014","unstructured":"Aoe M, Shimada A, Muraoka M, Washio K, Nakamura Y, Takahashi T, et al. ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases. Int J Hematol. 2014;99:609\u201315.","journal-title":"Int J Hematol"},{"key":"1788_CR12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/bmt.2012.246","volume":"48","author":"M W\u00f6lfl","year":"2013","unstructured":"W\u00f6lfl M, Langhammer F, Wiegering V, Eyrich M, Schlegel PG. Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues. Bone Marrow Transplant. 2013;48:875\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1788_CR13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","volume":"39","author":"C Sillaber","year":"2009","unstructured":"Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, B\u00f6hm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u00a0mg daily. Eur J Clin Invest. 2009;39:1098\u2013109.","journal-title":"Eur J Clin Invest"},{"key":"1788_CR14","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, et al. Expansion of highly differentiated CD8\u00a0+\u00a0T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587\u201397.","journal-title":"Leukemia"},{"key":"1788_CR15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27:914\u201324.","journal-title":"Leukemia"},{"key":"1788_CR16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135\u20139.","journal-title":"Haematologica"},{"key":"1788_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","volume":"47","author":"K Ikeda","year":"2006","unstructured":"Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47:155\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1788_CR18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12185-009-0386-2","volume":"90","author":"BW Kang","year":"2009","unstructured":"Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol. 2009;90:383\u20137.","journal-title":"Int J Hematol"},{"key":"1788_CR19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3748\/wjg.v19.i8.1318","volume":"19","author":"GM Lai","year":"2013","unstructured":"Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19:1318\u201321.","journal-title":"World J Gastroenterol"},{"key":"1788_CR20","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lor\u00e9 K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473\u20139.","journal-title":"Blood"},{"key":"1788_CR21","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","volume":"18","author":"K Cwynarski","year":"2004","unstructured":"Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18:1332\u20139.","journal-title":"Leukemia"},{"key":"1788_CR22","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","volume":"12","author":"J Chen","year":"2008","unstructured":"Chen J, Schmitt A, Chen B, Rojewski M, R\u00fcbeler V, Fei F, et al. Nilotinib hampers the proliferation and function of CD8\u00a0+\u00a0T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107\u201318.","journal-title":"J Cell Mol Med"},{"key":"1788_CR23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1440-1746.1998.tb00539.x","volume":"13","author":"YF Liaw","year":"1998","unstructured":"Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol. 1998;13:14\u201320.","journal-title":"J Gastroenterol Hepatol"},{"key":"1788_CR24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jac\/dkn014","volume":"61","author":"J Sheldon","year":"2008","unstructured":"Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61:766\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1788_CR25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3851\/IMP1499","volume":"15","author":"SA Locarnini","year":"2010","unstructured":"Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther. 2010;15:451\u201361.","journal-title":"Antivir Ther"},{"key":"1788_CR26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/lt.23935","volume":"20","author":"M Ishigami","year":"2014","unstructured":"Ishigami M, Honda T, Ishizu Y, Onishi Y, Kamei H, Hayashi K, et al. Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients. Liver Transpl. 2014;20:1211\u201320.","journal-title":"Liver Transpl"},{"key":"1788_CR27","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood-2003-05-1403","volume":"102","author":"TH Westhoff","year":"2003","unstructured":"Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102:1930.","journal-title":"Blood"},{"key":"1788_CR28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jmv.24115","volume":"87","author":"H Kamitsukasa","year":"2015","unstructured":"Kamitsukasa H, Iri M, Tanaka A, Nagashima S, Takahashi M, Nishizawa T, et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol. 2015;87:589\u2013600.","journal-title":"J Med Virol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-015-1788-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1788-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:24Z","timestamp":1559452284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-015-1788-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1788-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,5]]}}}